MARKET

PRTK

PRTK

Paratek Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.29
+0.40
+8.18%
After Hours: 5.29 0 0.00% 18:26 09/24 EDT
OPEN
4.900
PREV CLOSE
4.890
HIGH
5.42
LOW
4.900
VOLUME
605.13K
TURNOVER
--
52 WEEK HIGH
11.24
52 WEEK LOW
4.510
MARKET CAP
258.12M
P/E (TTM)
-4.4168
1D
5D
1M
3M
1Y
5Y
34 Stocks Moving In Friday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08.
Benzinga · 1d ago
Bret Jensen: Paratek Deal Shows Promise
While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.
TheStreet.com · 1d ago
ZIVO Bioscience, Pieris Pharmaceuticals leads healthcare gainers; Kintara Therapeutics, Onconova Therapeutics among major losers
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics (NASDAQ:CAPR) +4%. Losers: Kintara Therapeutics (NASDAQ:KTRA) -...
Seekingalpha · 1d ago
BRIEF-Paratek Pharmaceuticals Presenting New Data For NUZYRA At IDWeek 2021
reuters.com · 2d ago
Paratek To Present New Data For NUZYRA At IDWeek 2021 Wednesday, Sept. 29
Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infections BOSTON,
Benzinga · 2d ago
Paratek Pharmaceuticals Presenting New Data for NUZYRA(R) (omadacycline) at IDWeek 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting.
GlobeNewswire · 2d ago
How Good Are Paratek Pharmaceuticals's Earnings? | Return On Capital Employed
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also posted a total of $57.49 million in sales, a 249.98% increase since Q1.
Benzinga · 09/17 14:37
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government...
GlobeNewswire · 09/09 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTK. Analyze the recent business situations of Paratek Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTK stock price target is 21.75 with a high estimate of 34.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 167
Institutional Holdings: 33.33M
% Owned: 68.30%
Shares Outstanding: 48.79M
TypeInstitutionsShares
Increased
35
935.88K
New
24
1.29M
Decreased
33
1.64M
Sold Out
15
302.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Executive Director
Michael Bigham
President
Adam Woodrow
Chief Executive Officer/Director
Evan Loh
General Counsel/Secretary
William Haskel
Other
Randall Brenner
Independent Director
Minnie Baylor-Henry
Independent Director
Thomas Dietz
Independent Director
Timothy Franson
Independent Director
Rolf Hoffmann
Independent Director
Kristine Peterson
Independent Director
Robert Radie
Independent Director
Jeffrey Stein
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 1.33
06/04/2014
About PRTK
Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.